Finance

Beta
Lists
BH3:FRA
PTC Therapeutics, Inc.
€59.20
+2.35%
(+1.36) 1D
Jun 5, 8:12:45 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BH3...
Open
€59.20
High
€59.20
Low
€59.20
Mkt. cap
5.86B
Avg. vol.
0.00
Volume
0.00
52-wk high
€75.00
52-wk low
€36.60
No. of employees
991
Open
€59.20
High
€59.20
Low
€59.20
Mkt. cap
5.86B
Avg. vol.
0.00
Volume
0.00
52-wk high
€75.00
52-wk low
€36.60
No. of employees
991
News stories
From sources across the web
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
178.88M
211.01M
164.68M
272.55M
Cost of goods sold
124.41M
115.94M
140.08M
39.96M
Cost of revenue
124.41M
115.94M
140.08M
39.96M
Research and development expenses
-
-
-
89.74M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
85.26M
84.05M
96.87M
86.18M
Operating expense
89.32M
91.58M
106.22M
187.51M
Total operating expenses
213.73M
207.52M
246.30M
227.46M
Operating income
-34.86M
3.49M
-81.62M
45.09M
Other non operating income
2.96M
102.00K
-7.65M
-1.00M
EBT including unusual items
-71.05M
-23.07M
-139.08M
-2.46M
EBT excluding unusual items
-70.95M
-31.40M
-150.16M
-3.55M
Income tax expense
-6.20M
-38.97M
-4.12M
347.00K
Effective tax rate
8.73%
168.89%
2.96%
-14.09%
Other operating expenses
-
-
-
-
Net income
-64.85M
15.90M
-134.96M
-2.81M
Net profit margin
-36.25%
7.53%
-81.96%
-1.03%
Earnings per share
-0.83
0.19
-1.80
-0.03
Interest and investment income
20.99M
19.09M
2.14M
17.98M
Interest expense
-51.35M
-51.68M
-57.32M
-67.02M
Net interest expenses
-30.36M
-32.59M
-55.19M
-49.03M
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.28M
14.60M
-68.72M
60.50M
Gain or loss from assets sale
-
53.00K
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer